L
Lotta Ljung
Researcher at Umeå University
Publications - 59
Citations - 1737
Lotta Ljung is an academic researcher from Umeå University. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 13, co-authored 46 publications receiving 1299 citations. Previous affiliations of Lotta Ljung include Karolinska Institutet & Uppsala University.
Papers
More filters
Journal ArticleDOI
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Anja Strangfeld,Martin Schäfer,Milena A. Gianfrancesco,Saskia Lawson-Tovey,Jean W. Liew,Lotta Ljung,Elsa F Mateus,Christophe Richez,Maria José Santos,Gabriela Schmajuk,Carlo Alberto Scirè,Emily Sirotich,Jeffrey A. Sparks,Paul Sufka,Thierry Thomas,Laura Trupin,Zachary S. Wallace,Sarah Al-Adely,Javier Bachiller-Corral,Suleman Bhana,Patrice Cacoub,Loreto Carmona,Ruth Costello,Wendy Costello,Laure Gossec,Rebecca Grainger,Eric Hachulla,Rebecca Hasseli,Jonathan S. Hausmann,Kimme L. Hyrich,Zara Izadi,Lindsay Jacobsohn,Patricia P. Katz,Lianne Kearsley-Fleet,Philip Robinson,Philip Robinson,Jinoos Yazdany,Pedro Machado +37 more
TL;DR: In this paper, the authors determined factors associated with COVID-19-related death in people with rheumatic diseases, including age, sex, smoking status, comorbidities, diagnosis, disease activity and medications.
Journal ArticleDOI
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
R. F. van Vollenhoven,R. F. van Vollenhoven,Sofia Ernestam,Pierre Geborek,Ingemar F Petersson,L Cöster,E. Waltbrand,Agneta Zickert,J. Theander,Ake Thorner,H. Hellstrom,Annika Teleman,Christina Dackhammar,F. Akre,Kristina Forslind,Lotta Ljung,R. Oding,A. Chatzidionysiou,M. Wornert,Johan Bratt +19 more
TL;DR: In patients with early rheumatoid arthritis in whom methotrexate treatment failed, addition of a tumour necrosis factor antagonist to methot Rexate monotherapy is clinically superior to addition of conventional disease-modifying antirheumatic drugs.
Journal ArticleDOI
Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study.
Lena Innala,Bozena Möller,Lotta Ljung,Staffan Magnusson,T Smedby,Anna Södergren,Marie-Louise Öhman,Solbritt Rantapää-Dahlqvist,Solveig Wållberg-Jonsson +8 more
TL;DR: The occurrence of new CV events in very early RA was explained by traditional CV risk factors and was potentiated by high disease activity, which may have implications for cardio-protective strategies in RA.
Journal ArticleDOI
Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still's Disease. An Open, Randomized, Multicenter Study
Dan Nordström,Ann Knight,Reijo Luukkainen,Ronald F van Vollenhoven,Vappu Rantalaiho,Anna Kajalainen,Johan G. Brun,Anne Prøven,Lotta Ljung,Hannu Kautiainen,Tom Pettersson +10 more
TL;DR: Anakinra induced more beneficial responses than DMARD in patients with AOSD and was favored in the open-label extension phase and wasavored in the OLE phase.
Journal ArticleDOI
Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study
Lena Innala,Ewa Berglin,Bozena Möller,Lotta Ljung,T Smedby,Anna Södergren,Staffan Magnusson,Solbritt Rantapää-Dahlqvist,Solveig Wållberg-Jonsson +8 more
TL;DR: In this paper, the impact of age at disease onset on prognostic risk factors and treatment in patients with early disease was evaluated, and the results of multiple regression analyses supported the findings regarding the impact on chosen treatment.